SCHEMBL7670478

SCHEMBL7670478

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc(NC(=O)c2ccccc2Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.56
POLB P06746 1/20 0.56
ALDH1A1 P00352 3/20 0.55
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KMT2A Q03164 1/20 0.55
HSD17B10 Q99714 1/20 0.50
PCTP Q9UKL6 1/20 0.48
GPR27 Q9NS67 6/20 0.47
SMO Q99835 1/20 0.47
AVPR2 P30518 2/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7671600 0.88 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2KMT2AHSD17B10
SCHEMBL7665180 0.87 KDM4E (0.56) TP53POLBLMNASMN1; SMN2KMT2A
SCHEMBL7669835 0.86 RXFP1 (0.61) TP53POLBALDH1A1LMNASMN1; SMN2
SCHEMBL7669734 0.85 MEN1 (0.52) TP53POLBALDH1A1LMNAKMT2A
SCHEMBL7669548 0.84 ALDH1A1 (0.64) POLBALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL7582747 0.84 LMNA (0.65) POLBALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL7675575 0.83 TP53 (0.65) TP53POLBALDH1A1LMNASMN1; SMN2
SCHEMBL7675914 0.83 LMNA (0.65) TP53LMNASMN1; SMN2MAPTGAA
SCHEMBL7663139 0.82 POLB (0.62) POLBALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL7671859 0.82 PRMT1 (0.56) TP53POLBALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed